Optical redox ratio differentiates breast cancer cell lines based on estrogen receptor status.
Autofluorescence spectroscopy is a powerful imaging technique that exploits endogenous fluorophores. The endogenous fluorophores NADH and flavin adenine dinucleotide (FAD) are two of the principal electron donors and acceptors in cellular metabolism, respectively. The optical oxidation-reduction (redox) ratio is a measure of cellular metabolism and can be determined by the ratio of NADH/FAD. We hypothesized that there would be a significant difference in the optical redox ratio of normal mammary epithelial cells compared with breast tumor cell lines and that estrogen receptor (ER)-positive cells would have a higher redox ratio than ER-negative cells. To test our hypothesis, the optical redox ratio was determined by collecting the fluorescence emission for NADH and FAD via confocal microscopy. We observed a statistically significant increase in the optical redox ratio of cancer compared with normal cell lines (P < 0.05). Additionally, we observed a statistically significant increase in the optical redox ratio of ER(+) breast cancer cell lines. The level of ESR1 expression, determined by real-time PCR, directly correlated with the optical redox ratio (Pearson's correlation coefficient = 0.8122, P = 0.0024). Furthermore, treatment with tamoxifen and ICI 182,870 statistically decreased the optical redox ratio of only ER(+) breast cancer cell lines. The results of this study raise the important possibility that fluorescence spectroscopy can be used to identify subtypes of breast cancer based on receptor status, monitor response to therapy, or potentially predict response to therapy. This source of optical contrast could be a potentially useful tool for drug screening in preclinical models.
Ostrander
Julie Hanson
JH
Department of Medicine, Division of Medical Oncology, Duke University Medical Center and Department of Biomedical Engineering, Fitzpatrick Institute for Photonics, Duke University, Durham, NC 27710, USA. julie.ostrander@duke.edu
McMahon
Christine M
CM
Lem
Siya
S
Millon
Stacy R
SR
Brown
J Quincy
JQ
Seewaldt
Victoria L
VL
Ramanujam
Nimmi
N
D001943:Breast Neoplasms / Q000188:drug therapy / Q000235:genetics / Q000378:metabolism*; D045744:Cell Line, Tumor; D004847:Epithelial Cells / Q000166:cytology / Q000378:metabolism; D004958:Estradiol / Q000031:analogs & derivatives / Q000494:pharmacology; D020847:Estrogen Receptor Modulators / Q000494:pharmacology; D047628:Estrogen Receptor alpha / Q000096:biosynthesis / Q000235:genetics / Q000378:metabolism*; D005260:Female; D005182:Flavin-Adenine Dinucleotide / Q000378:metabolism; D000077267:Fulvestrant; D006801:Humans; D042361:Mammary Glands, Human / Q000166:cytology / Q000378:metabolism; D018613:Microscopy, Confocal / Q000379:methods; D009243:NAD / Q000378:metabolism; D010084:Oxidation-Reduction; D012333:RNA, Messenger / Q000096:biosynthesis / Q000235:genetics; D013629:Tamoxifen / Q000494:pharmacology
C506487:ESR1 protein, human; D020847:Estrogen Receptor Modulators; D047628:Estrogen Receptor alpha; D012333:RNA, Messenger; D013629:Tamoxifen; D009243:NAD; D005182:Flavin-Adenine Dinucleotide; D000077267:Fulvestrant; D004958:Estradiol
Oncogene. 2006 Aug 7;25(34):4647-62
16892079
Endocrinology. 1999 Aug;140(8):3602-8
10433217
Biochim Biophys Acta. 1992 Feb 3;1133(3):301-6
1531302
Biochim Biophys Acta. 2009 Jul;1793(7):1128-43
19348861
Cancer Res. 1997 Aug 15;57(16):3486-93
9270017
Proc Natl Acad Sci U S A. 2007 Dec 4;104(49):19494-9
18042710
FASEB J. 2001 Apr;15(6):907-15
11292650
Photochem Photobiol. 2003 Nov;78(5):462-9
14653577
Cancer Res. 2000 Feb 15;60(4):916-21
10706105
J Steroid Biochem Mol Biol. 1992 Sep;43(1-3):189-95
1525059
Cancer Res. 2002 Feb 1;62(3):682-7
11830520
Cell Biochem Funct. 1988 Jul;6(3):197-202
3409480
J Biomed Opt. 2009 Mar-Apr;14(2):024010
19405740
J Photochem Photobiol B. 2009 Apr 2;95(1):46-57
19179090
J Biol Chem. 1979 Jun 10;254(11):4764-71
220260
Cancer Treat Rev. 2003 Dec;29(6):541-9
14585264
Photochem Photobiol. 2005 Jan-Feb;81(1):125-34
15535738
Mol Interv. 2006 Feb;6(1):26-35
16507748
Mol Pharmacol. 2005 Oct;68(4):959-65
15994367
Ann Surg Oncol. 2004 Jan;11(1):65-70
14699036
Int J Cancer. 2008 Jan 15;122(2):363-71
17935126
Metabolism. 2002 Nov;51(11):1397-401
12404187
J Cell Physiol. 2005 Mar;202(3):654-62
15389572
Cancer Cell. 2008 Jun;13(6):472-82
18538731
Biotechnol Appl Biochem. 2003 Feb;37(Pt 1):45-50
12578551
Proteomics. 2005 Dec;5(18):4936-45
16237733
Science. 1956 Feb 24;123(3191):309-14
13298683
Nature. 2006 May 25;441(7092):437-43
16724055